Journal
BONE
Volume 42, Issue 2, Pages 332-340Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2007.10.004
Keywords
tissue engineering; tissue regeneration; bone; growth factor; TGF beta 3
Categories
Funding
- NIDCR NIH HHS [RC2 DE020767-02, R01 DE015391, RC2 DE020767, DE013964, R01 DE013964, DE015391] Funding Source: Medline
Ask authors/readers for more resources
Craniosynostosis occurs in one of 2500 live human births and may manifest as craniofacial disfiguration, seizure, and blindness. Craniotomy is performed to reshape skull bones and resect synostosed cranial sutures. We demonstrate for the first time that autologous mesenchymal stem cells (MSCs) and controlled-released TGF beta 3 reduced surgical trauma to localized osteotomy and minimized osteogenesis in a rat craniosynostosis model. Approximately 0.5mL tibial marrow content was aspirated to isolate mononucleated and adherent cells that were characterized as MSCs. Upon resecting the synostosed suture, autologous MSCs in collagen carriers with microencapsulated TGF beta 3 (1ng/mL) generated cranial suture analogs characterized as bone-soft tissue-bone interface by quantitative histomorphometric and mu CT analyses. Thus, surgical trauma in craniosynostosis can be minimized by a biologically viable implant. We speculate that proportionally larger amounts of human marrow aspirates participate in the healing of craniosynostosis defects in patients. The engineered soft tissue-bone interface may have implications in the repair of tendons, ligaments, periosteum and periodontal ligament. (c) 2007 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available